In situ hybridisation analysis of a homogeneously staining region at 11q23–24 in an acute myeloid leukaemia (M5) using yeast artificial chromosomes

1993 ◽  
Vol 7 (3) ◽  
pp. 123-127 ◽  
Author(s):  
Elisabeth Nacheva ◽  
Lyndal Kearney ◽  
Mark Bower ◽  
Tracy Chaplin ◽  
Edward Douek ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
In Situ Hybridisation ◽  
Artificial Chromosomes ◽  
Hybridisation Analysis ◽  
Yeast Artificial Chromosomes ◽  
Acute Myeloid

scholarly journals Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia

2020 ◽  
Vol 191 (5) ◽  
pp. 935-938
Author(s):  
Nya D. Nelson ◽  
Christine M. McMahon ◽  
Farah El‐Sharkawy Navarro ◽  
Craig W. Freyer ◽  
Jacquelyn J. Roth ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Therapy ◽  
In Situ Hybridisation ◽  
Fluorescence In Situ Hybridisation ◽  
Acute Myeloid

E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib

2010 ◽  
Vol 63 (8) ◽  
pp. 737-740 ◽  
Author(s):  
Ayda Bennour ◽  
Nathalie Beaufils ◽  
Halima Sennana ◽  
Balkis Meddeb ◽  
Ali Saad ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Therapeutic Effect ◽  
In Situ Hybridisation ◽  
Fusion Transcript ◽  
Imatinib Treatment ◽  
Fluorescence In Situ Hybridisation ◽  
Fusion Transcripts ◽  
Hybridisation Analysis

The development of imatinib is a milestone in the treatment of chronic myeloid leukaemia (CML), and its therapeutic effect has been extensively investigated in patients with CML who carry M-bcr and m-bcrBCR–ABL fusion transcripts. However, knowledge about its therapeutic effect on patients with CML who have the rare BCR–ABL fusion transcript e19a2 (μ-bcr) remains sparse. This report describes a patient with Philadelphia-positive chronic myeloid leukaemia with e19a2 rearrangement, in whom E355G mutation had been acquired. The patient was resistant to imatinib treatment based on conventional cytogenetic and fluorescence in situ hybridisation analysis.

The acute myeloid leukaemia market

2019 ◽  
Vol 19 (4) ◽  
pp. 233-234
Author(s):  
Jorrit Schaefer ◽  
Sorcha Cassidy ◽  
Rachel M. Webster
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document